Compugen Ltd.
CGENHealthcareNASDAQBiotechnology · Last scanned Jul 22, 2026
Scan Results
Daily timeframePart of the healthcare sector, Compugen Ltd. (CGEN) is listed under Biotechnology. Valued at $235.5M, CGEN is a micro-cap name in its sector. The company's pipeline consists of COM701, an immuno-oncology pipeline program with an anti-PVRIG antibody; COM902, a therapeutic anti-TIGIT antibody, are in Phase 1 clinical trials and have been evaluated for the treatment of solid tumors as a monotherapy and in combination of PVRIG/PD-1 and PVRIG/TIGIT, as well as PVRIG/PD-1/TIGIT blockade; Bapotulimab, a therapeutic antibody targeting ILDR2 that is evaluated in Phase I clinical trials in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti- PD-1/TIGIT bispecific antibody, which is in Phase III clinical study in patients with advanced or metastatic non-small cell lung cancer.
Market Cap
$235.5M
Beta
2.77
P/E (TTM)
6.07
P/E (Fwd)
-6.82
EPS (TTM)
$0.41
EPS (Fwd)
$-0.36
ROE
45.7%
ROA
14.7%
Cash
$134.9M
Total Debt
$2.9M
Free CF
—
52W Change
60.7%
Annual Financials
Cash vs Debt
Where CGEN stands vs its 150-day and 200-day moving averages
As of the July 13, 2026 close, CGEN finished 11.68% above its 150-day moving average ($2.14) and 18.32% above its 200-day moving average ($2.02). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is CGEN overbought or oversold?
At the July 13, 2026 close, CGEN's RSI(14) was 76.4, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $134.9M in cash and $2.9M in debt, CGEN maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. ROE of 45.7% points to exceptionally high capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Return on assets of 14.7% further supports the picture of efficient asset utilization. Revenue has grown from $7.5M (2022) to $72.8M (2025), reflecting a 870% increase over the period.
With a beta above 1.5, CGEN tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Compugen Ltd. and its sector.